Zeit | Aktuelle Nachrichten Sprache:
Alle DE EN | Leser | Medien | ||
---|---|---|---|---|---|
01.10. | Orexo AB: Orexo strengthens innovation and research with move to new premises | 40 | GlobeNewswire (Europe) | Uppsala, Sweden, October 1, 2025 - Orexo AB (Publ.), (STO:ORX) (OTCQX:ORXOY) is taking the next step in its development journey by relocating to new, modern premises in Uppsala Science Park. The move... ► Artikel lesen | |
30.09. | Orexo US Awarded $8M in Funding by BARDA | 1 | Contract Pharma | ||
29.09. | Orexo AB: Orexo US Awarded USD 8 Million by BARDA for OX390 Development Partnership | 272 | GlobeNewswire (Europe) | Uppsala, Sweden - September 29, 2025 - Orexo AB (Publ.), (STO:ORX) (OTCQX:ORXOY), today announced its wholly owned US subsidiary, Orexo US, Inc., has been awarded USD 8 million in funding by the Biomedical... ► Artikel lesen | |
05.09. | Orexo's AmorphOX technology may pave the way for intranasal GLP-1 medication | 839 | PR Newswire | A preclinical pharmacokinetic in-vivo study has been conducted in which the AmorphOX® technology was used to develop three powder-based intranasal formulations with semaglutide, which were... ► Artikel lesen | |
29.08. | Seminar: IP That Matters - Behind Orexo's Milestone Patent Win at the US Court | 331 | PR Newswire | UPPSALA, Sweden, Aug. 29, 2025 /PRNewswire/ -- Orexo (publ.), (STO: ORX) (OTCQX: ORXOY) in collaboration with its advisory international law firms Potter Clarkson LLP and Steptoe LLP, will... ► Artikel lesen | |
16.07. | Orexo Q2 2025 slides: Maintains full-year outlook despite FX headwinds | 1 | Investing.com | ||
16.07. | Orexo hält trotz Währungsgegenwind an Jahresprognose für 2025 fest | 1 | Investing.com Deutsch | ||
16.07. | Orexo AB: Orexo Q2 2025 Interim Report | 189 | GlobeNewswire (Europe) | 2025 outlook remains amid currency headwinds and non-recurring effectQ2 2025 highlights› Total net revenues of SEK 118.2 m (154.0), including a non-recurring rebate payment of SEK 8.9 m› EBITDA of SEK... ► Artikel lesen | |
OREXO Aktie jetzt für 0€ handeln | |||||
02.06. | Orexo to present clinical data for OX640 at the EAACI Congress | 264 | PR Newswire | OX640 is a nasal rescue medication with powder-based epinephrine for the treatment of severe allergic reactions (including anaphylaxis) and is based on the proprietary AmorphOX® technologyEAACI... ► Artikel lesen | |
06.05. | Orexo Q1 2025 slides: stable revenue growth amid pipeline advancements | 1 | Investing.com | ||
06.05. | Orexo AB: Orexo Q1 2025 Interim Report | 219 | GlobeNewswire (Europe) | Q1 2025 highlights› Total net revenues of SEK 146.2 m (139.3)› EBITDA of SEK 5.9 m (15.9)› Net earnings of SEK -15.9 m (-8.9)› US Commercial segment net revenues of SEK 133.0 m (129.3), in local currency... ► Artikel lesen | |
10.04. | Orexo announces positive data for powder-based intranasal vaccine formulated with the AmorphOX technology | 404 | PR Newswire | The study was conducted in partnership with Abera Bioscience, a platform and vaccine developer with over 30 years of research in the medical, molecular and microbiological fields.Both formulations... ► Artikel lesen | |
06.02. | Orexo AB: Orexo Interim Report Q4 2024, incl. Full Year Report | 183 | GlobeNewswire (Europe) | Q4 2024 highlights› Total net revenues of SEK 160.3 m (166.0)› EBITDA of SEK 28.9 m (12.4)› Impairment of intangible assets Deprexis® of SEK 71.1 m (0) and Vorvida® of SEK 28.1 m (0)› Net earnings of... ► Artikel lesen | |
10.01. | Orexo announces positive topline data from clinical study of OX640 in subjects with and without allergic rhinitis | 488 | PR Newswire | OX640 is a nasal rescue medication with powder-based epinephrine for the treatment of allergic reactions (incl. anaphylaxis) and is based on the proprietary AmorphOX® technology.The clinical... ► Artikel lesen | |
17.12.24 | Orexo enters into collaboration with Abera to develop nasal powder vaccines based on the AmorphOX technology | 515 | PR Newswire | The collaboration is in line with Orexo's strategy to broaden the use of its powder-based drug delivery technology AmorphOX®.Abera is a developer of mucosal vaccines and has several preclinical... ► Artikel lesen | |
02.12.24 | Orexo AB: Orexo and GAIA agree to terminate the partnership for Deprexis | 434 | GlobeNewswire (Europe) | Uppsala, Sweden - December 2, 2024 - Orexo AB (publ.), (STO:ORX) (OTCQX:ORXOY), today announces that Orexo AB and GAIA AG have decided to terminate the partnership agreement, covering the rights for... ► Artikel lesen | |
25.10.24 | Orexo initiates new study of OX640 in participants with allergic rhinitis | 374 | PR Newswire | OX640 is an intranasal rescue medication for the treatment of severe allergic reactions (incl. anaphylaxis) with powder-based epinephrine.OX640 is based on Orexo's proprietary drug delivery... ► Artikel lesen | |
24.10.24 | Orexo Interim Report Q3 2024 | 521 | PR Newswire | UPPSALA, Sweden, Oct. 24, 2024 /PRNewswire/ --
Q3 2024 highlights
› Total net revenues of SEK 136.5 m (156.1)
› EBITDA of SEK -0.7 m (-9.5)
› Net earnings of SEK -41.9... ► Artikel lesen |
Unternehmen / Aktien | Aktienkurs | % | Top-Nachrichten | ||
---|---|---|---|---|---|
AURORA CANNABIS | 4,565 | +0,11 % | Piramal Pharma Solutions Implements POD Method at Aurora API Facility | ||
ABBVIE | 199,40 | +0,40 % | Abbvie - ABBV: Berenberg-Bank JETZT mit "KAUFEN"! | Kursziel 270 USD! Skyrizi & Rinvoq lösen Humira als Umsatzbringer für Abbvie ab! Marktführer bei Immunologie! Abbvie (ABBV) - ISIN US00287Y1091 Rückblick: Mit einem Kursplus von rund 30 Prozent beeindruckte... ► Artikel lesen | |
TILRAY BRANDS | 1,631 | +10,39 % | Tilray-Aktie explodiert nach Quartalszahlen - echter Turnaround oder Strohfeuer? | ||
BRISTOL-MYERS SQUIBB | 38,180 | +0,82 % | Nach Novo Nordisk: Jetzt schlägt auch Bristol Myers Squibb zu | Das Übernahmekarussell im Biotechnologie-Sektor dreht sich dynamisch weiter. Nachdem Novo Nordisk die milliardenschwere Übernahme des AKTIONÄR-Tipps Akero am Donnerstag bekanntgegeben hat, kann auch... ► Artikel lesen | |
TEVA | 17,200 | -0,29 % | Biotech: Kleine Innovationen, große Wirkung mit Teva Pharmaceutical, BioNxt, Lonza Group | Wer in Biotech investiert, der wünscht sich, das nächste große Ding im Depot zu haben: Wirkstoffe, die alles revolutionieren, Technologien, die den Unterschied machen. Tatsächlich gibt es in der Biotechnologie... ► Artikel lesen | |
BAUSCH HEALTH | 5,280 | +1,27 % | Bausch Health Companies Inc.: Bausch Health Announces Results of Special Meeting of Shareholders | LAVAL, QC / ACCESS Newswire / October 9, 2025 / Bausch Health Companies Inc. (the "Company") (NYSE:BHC)(TSX:BHC) today announced the results of the special meeting of shareholders held on October 7... ► Artikel lesen | |
BIONANO GENOMICS | 1,950 | -8,45 % | Bionano Genomics: Bionano to Participate in the H.C. Wainwright @ Home Event | ||
OPKO HEALTH | 1,300 | -0,37 % | OPKO Health, Inc.: OPKO Health and Entera Bio Abstract for First-in-Class Dual GLP-1/Glucagon Tablet Candidate for Patients with Obesity and Metabolic Disorders Selected for Presentation at the ENDO 2025 Annual Meeting | MIAMI and JERUSALEM, June 25, 2025 (GLOBE NEWSWIRE) -- OPKO Health, Inc. (NASDAQ: OPK) and Entera Bio Ltd. (NASDAQ: ENTX) ("Entera") today announced that new pharmacologic and pharmacokinetic in vivo... ► Artikel lesen | |
JAGUAR HEALTH | 2,070 | -10,00 % | Jaguar Health, Inc.: Jaguar Health Completes Meeting with FDA for Advice on Development Pathways to Advance Ongoing Crofelemer Trial for Potential Approval for Treatment of Pediatric Indication Microvillus Inclusion Disease | Additional update: Results of ongoing investigator-initiated proof-of-concept trial in United Arab Emirates (UAE) demonstrate further reduction of total parenteral support (PS) (comprised of total parenteral... ► Artikel lesen | |
MALLINCKRODT | - | - | Mallinckrodt plc - 8-K, Current Report | ||
AVALO THERAPEUTICS | 12,080 | +0,67 % | Avalo Therapeutics, Inc. - 8-K, Current Report | ||
BAYER | 27,980 | -0,78 % | DAX fest, Gold, Bitcoin, Nikkei mit Rekorden: Redcare, Nordex, Merck, Siemens Energy, Bayer ... | Der DAX hat sich am Freitag nach einer starken Woche bei 24.378,80 Punkten ins Wochenende verabschiedet. Auf Wochensicht konnte er 2,7 Prozent zulegen. Zum Start in die neue Woche dürfte es noch ein... ► Artikel lesen | |
MERCK KGAA | 116,10 | -1,74 % | Unilever Appoints Merck CEO Belén Garijo López as Independent Non-Executive Director | ||
NOVO NORDISK | 49,510 | -2,39 % | Trader-Interview mit Rene Berteit: Rheinmetall, Novo Nordisk, Nvidia, Tesla & Siemens AG | In dieser Ausgabe des Trader-Interviews sprechen Andreas Bernstein und Rene Berteit über spannende Chancen bei .. ► Artikel lesen | |
METSERA | 52,85 | +0,48 % | Metsera, Inc.: Metsera Reports Positive Phase 2b Results for First- and Best-in-Class Ultra-long Acting GLP-1 RA Candidate MET-097i, Enabling Rapid Transition into Phase 3 | Placebo-subtracted mean weight loss up to 14.1% after 28 weeks with no plateau Potential for best-in-class tolerability with minimal diarrhea signal, 13% nausea, and 11% vomiting High study and... ► Artikel lesen |